Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2CNS 2Thoracic 1Sarcoma 1Other neoplasm 1Head & Neck 1Genitourinary 1Endocrine 1Breast 1

Conditions

Thyroid Cancer, Papillary 1Lymphatic Metastasis 1

Interventions

Everolimus 32Octreotide 15Cisplatin 14pasireotide 13Sunitinib 13Temozolomide 11pembrolizumab 10Etoposide 10Doxorubicin 10lanreotide 9Magnetic Resonance Spectroscopy 9Bevacizumab 9lutetium Lu 177 dotatate 8gallium Ga 68 dotatate 8Sorafenib 8Paclitaxel 83-Iodobenzylguanidine 8lenvatinib 7pazopanib 6Radiotherapy 6Positron Emission Tomography Computed Tomography 6surufatinib 5cabozantinib 5avelumab 5Thyrotropin Alfa 5Surgical Procedures, Operative 5Radiosurgery 5Nivolumab 5Mitotane 5Irinotecan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Spectrum Analysis × Endocrine × Clear all
NCT03470259 2024-04-16

TARGET

University Medical Center Groningen

Phase 1 Completed
19 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Lymphatic Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡